March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Twenty-Four-Hour Effects of Bimatoprost 0.01% Monotherapy On Intraocular Pressure and Ocular Perfusion Pressure
Author Affiliations & Notes
  • Jonathan D. Tung
    Ophthalmology, University of California-San Diego, La Jolla, California
  • Ali Tafreshi
    Ophthalmology, University of California-San Diego, La Jolla, California
  • Robert N. Weinreb
    Ophthalmology, University of California-San Diego, La Jolla, California
  • J. Rigby Slight
    Ophthalmology, University of California-San Diego, La Jolla, California
  • Felipe A. Medeiros
    Ophthalmology, University of California-San Diego, La Jolla, California
  • John H. Liu
    Ophthalmology, University of California-San Diego, La Jolla, California
  • Footnotes
    Commercial Relationships  Jonathan D. Tung, None; Ali Tafreshi, None; Robert N. Weinreb, Alcon (C), Allergan (C), Bausch & Lomb (C), Genentech (F), Merck Research Laboratories (C), Novartis (F); J. Rigby Slight, None; Felipe A. Medeiros, Alcon (F, C), Allergan (C), Carl Zeiss Meditec (F, C), Merck (F), Pfizer (F), Reichert (C); John H. Liu, Alcon (F), Allergan (F)
  • Footnotes
    Support  Allergan Inc., Research to Prevent Blindness (New York, NY).
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5091. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jonathan D. Tung, Ali Tafreshi, Robert N. Weinreb, J. Rigby Slight, Felipe A. Medeiros, John H. Liu; Twenty-Four-Hour Effects of Bimatoprost 0.01% Monotherapy On Intraocular Pressure and Ocular Perfusion Pressure. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5091.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the 24-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure (IOP) and ocular perfusion pressure (OPP).

Methods: : This was a prospective, open-label experimental study. Baseline data of 24-hour IOP in untreated patients were collected in a sleep laboratory. Measurements of IOP were taken using a pneumatonometer every 2 hours in the sitting and supine body positions during the 16-hour diurnal/wake period and in the supine position during the 8-hour nocturnal/sleep period. After baseline measurements were taken, patients were treated with bimatoprost 0.01% one time per day at bedtime for 4 weeks, then 24-hour IOP data were collected under the same laboratory conditions. Diurnal and nocturnal IOP and OPP means under bimatoprost 0.01% treatment were compared with baseline.

Results: : Sixteen patients with diagnosed primary open-angle glaucoma (POAG) or ocular hypertension (ages, 49-77 years) were included in the study. The diurnal and nocturnal IOP means were significantly lower under the bimatoprost 0.01% treatment than baseline in both the sitting and supine positions. The diurnal and nocturnal OPP means were significantly higher under treatment than baseline in both the sitting and supine positions.

Conclusions: : Bimatoprost 0.01% monotherapy significantly lowered IOP and increased OPP during the 24-hour period.

Clinical Trial: : http://www.clinicaltrials.gov NCT01271686

Keywords: intraocular pressure • optic flow • circadian rhythms 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×